Virax Biolabs Group (VRAX) Competitors

TherapeuticsMD (NASDAQ:TXMD) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking.

Which has more risk & volatility, TXMD or VRAX?

TherapeuticsMD has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Does the MarketBeat Community prefer TXMD or VRAX?

TherapeuticsMD received 385 more outperform votes than Virax Biolabs Group when rated by MarketBeat users. However, 100.00% of users gave Virax Biolabs Group an outperform vote while only 58.13% of users gave TherapeuticsMD an outperform vote.

Company	Underperform	Outperform
TherapeuticsMD	Outperform Votes 386 58.13%	Underperform Votes 278 41.87%
Virax Biolabs Group	Outperform Votes 1 100.00%	Underperform Votes No Votes

Which has preferable earnings and valuation, TXMD or VRAX?

Virax Biolabs Group has lower revenue, but higher earnings than TherapeuticsMD.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$1.76M	8.15	-$10.28M	N/A	N/A
Virax Biolabs Group	$84.87K	37.34	-$6.73M	N/A	N/A

Do institutionals & insiders have more ownership in TXMD or VRAX?

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 2.3% of TherapeuticsMD shares are owned by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the media refer more to TXMD or VRAX?

In the previous week, Virax Biolabs Group had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Virax Biolabs Group and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.63 beat Virax Biolabs Group's score of 0.30 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TherapeuticsMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Virax Biolabs Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is TXMD or VRAX more profitable?

Virax Biolabs Group has a net margin of 0.00% compared to TherapeuticsMD's net margin of -207.77%. Virax Biolabs Group's return on equity of 0.00% beat TherapeuticsMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-207.77%	-14.08%	-9.61%
Virax Biolabs Group	N/A	N/A	N/A

Do analysts prefer TXMD or VRAX?

Virax Biolabs Group has a consensus price target of $3.00, suggesting a potential upside of 206.06%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Virax Biolabs Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Virax Biolabs Group beats TherapeuticsMD on 12 of the 16 factors compared between the two stocks.